NEOK002 (ABL209): Redesigning an EGFRxMUC1 Bispecific TOP1i ADC With Promising Anti-Tumor Activity & Enhanced Therapeutic Window
- Selecting the target combination and validating
- Outlining how to differentiate NEOK002 from known EGFR and MUC1 targeting agents
- Exploring preclinical activity and toxicity of the bispecific ADC